Author:
Christoph Frank,Koch Tabea,Blaschke Simon,König Frank,Lebentrau Stefan,Wendler Johann,Schostak Martin
Publisher
Springer Science and Business Media LLC
Reference35 articles.
1. Verbreitung von Krebserkrankungen in Deutschland, Entwicklungen der Prävalenzen in Deutschland zwischen 1990 und 2010, Robert-Koch-Institut,
www.krebsdaten.de
2. Grotenhuis A et al. The effect of smoking and timing of smoking cessation on clinical outcome in non-muscle-invasive bladder cancer. Urol Oncol. 2015; http://doi.org/f258zj
3. Shang P et al. Intravesical bacillus Calmette-Guerin versus epirubicin for Ta and T1 bladder cancer. Cochrane Database Syst Rev. 2011; http://doi.org/brb8vn
4. Huncharek M et al. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res. 2001; 21: 765–976
5. Malmstrom P et al. An individual patient data-analysis of the long-term outcome of randomized studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle invasive bladder cancer. Eur Urol. 2009; 56: 247–56